20.57

2.54% 0.51

After Hours: 20.11 -0.46 -2.24%

Arrowhead Pharmaceuticals Inc (ARWR)

Overview News Price History Option Chain Financials Why ARWR Down? Discussions Forecast Stock Split

Arrowhead Pharmaceuticals Inc stock is traded at $20.57, with a volume of 778.15K. It is up +2.54% in the last 24 hours and up +9.30% over the past month. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Previous Close:

$20.06

Open:

$20.025

24h Volume:

778.15K

Relative Volume:

0.77

Market Cap:

$2.55B

Revenue:

$181.74M

Net Income/Loss:

$-296.81M

P/E Ratio:

-12.03

EPS:

-1.71

Net Cash Flow:

$-402.70M

1W Performance:

+2.95%

1M Performance:

+9.30%

6M Performance:

-15.83%

1Y Performance:

-26.93%

1-Day Range:

$19.63

$20.59

1-Week Range:

$19.20

$20.59

52-Week Range:

$17.05

$39.83

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name

Arrowhead Pharmaceuticals Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

626-696-4702

Address

177 E COLORADO BLVD, PASADENA, CA

Employee

525

Twitter

@ArrowheadPharma

Next Earnings Date

2024-11-27

Latest SEC Filings

ARWR's Discussions on Twitter

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-23	Initiated	BofA Securities	Buy
Sep-19-23	Initiated	Citigroup	Neutral
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-19-22	Resumed	Goldman	Buy
Aug-06-21	Reiterated	Chardan Capital Markets	Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	UBS	Buy
Nov-19-20	Initiated	Citigroup	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-08-20	Upgrade	Oppenheimer	Perform → Outperform
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform
Mar-17-20	Initiated	Goldman	Neutral
Jan-21-20	Initiated	SVB Leerink	Underperform
Dec-13-19	Initiated	Oppenheimer	Perform
Nov-29-19	Reiterated	Chardan Capital Markets	Buy
Nov-27-19	Reiterated	B. Riley FBR	Buy
Nov-25-19	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-24-19	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-22-19	Reiterated	Chardan Capital Markets	Buy
Oct-03-19	Initiated	Robert W. Baird	Outperform
Sep-07-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-06-18	Reiterated	Chardan Capital Markets	Buy
Aug-08-18	Reiterated	Cantor Fitzgerald	Overweight
Jul-02-18	Reiterated	Chardan Capital Markets	Buy

View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

07:31 AM

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - The Bakersfield Californian

07:31 AM

Nov 04, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace

Nov 04, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace

Nov 04, 2024

Nov 03, 2024

abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Arrowhead Launches FCS Awareness Campaign - Baystreet.ca

Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow

Nov 01, 2024

In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Nov 01, 2024

Oct 31, 2024

International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 31, 2024

Oct 30, 2024

(ARWR) Long Term Investment Analysis - Stock Traders Daily

Oct 30, 2024

Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 30, 2024

Oct 28, 2024

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat

Oct 28, 2024

Oct 21, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat

Oct 21, 2024

Oct 20, 2024

(ARWR) Trading Signals - Stock Traders Daily

Oct 20, 2024

Oct 18, 2024

Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 18, 2024

Oct 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024

Oct 16, 2024

State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com

Oct 16, 2024

Oct 15, 2024

Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail

Oct 15, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace

Oct 15, 2024

Oct 11, 2024

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Oct 11, 2024

Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com

Oct 11, 2024

Oct 10, 2024

Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 10, 2024

Oct 09, 2024